Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Relief of discomfort associated with acute painful musculoskeletal conditions,Off-label: tension headache, migraine
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Orphenadrine: hepatic N-demethylation and hydroxylation via CYP450 enzymes; Aspirin: hydrolysis to salicylate and conjugation with glycine and glucuronic acid; Caffeine: hepatic metabolism via CYP1A2.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Orphenadrine: ~30% (albumin); Aspirin: 80-90% (albumin, saturable); Caffeine: 25-36% (albumin).
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Orphenadrine: ~2.5 L/kg (widespread, CNS penetration); Aspirin: 0.15-0.2 L/kg (low, primarily extracellular); Caffeine: 0.6-0.8 L/kg.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: Orphenadrine ~90%; Aspirin 40-50% (first-pass hydrolysis to salicylate); Caffeine ~100%.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), extend dosing interval to every 12-24 hours. No adjustment for mild impairment (Cr Cl 60-89 m L/min).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% or extend interval to every 12-24 hours. Use with caution in Child-Pugh class A.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Not recommended for pediatric use due to aspirin's association with Reye's syndrome and lack of safety data for orphenadrine in children.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Use lower end of dosing range (e.g., 1 tablet every 12 hours) due to increased sensitivity to anticholinergic effects and risk of aspirin-induced gastrointestinal bleeding. Avoid use in patients >80 years if possible.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
No FDA black box warning.
None
Avoid in patients with glaucoma, prostatic hypertrophy, or urinary retention due to anticholinergic effects; caution in elderly and those with cardiovascular disease; risk of GI bleeding with aspirin; limit caffeine intake to avoid excessive stimulation.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to any component; patients with angle-closure glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcer, prostatic hypertrophy, or bladder neck obstruction; severe renal or hepatic impairment; bleeding disorders; concurrent use of anticoagulants.
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Avoid high-tyramine foods (e.g., aged cheeses, cured meats) due to orphenadrine's anticholinergic effects on gut motility. Evening meals high in caffeine may worsen insomnia. Aspirin absorption is delayed by food, but taking with food reduces GI irritation.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may increase miscarriage risk. Second trimester: Aspirin at high doses may impair fetal renal function; orphenadrine and caffeine effects are not well-studied. Third trimester: Aspirin use after 30 weeks gestation increases risk of premature closure of ductus arteriosus and oligohydramnios; orphenadrine may cause neonatal withdrawal; caffeine may accumulate.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Aspirin and its metabolites are excreted into breast milk (M/P ratio ~0.04-0.27 for salicylate); orphenadrine is not known to be excreted; caffeine is excreted (M/P ratio ~0.5-0.76). Theoretical risk of Reye's syndrome with aspirin, and irritability in infant with caffeine. Use caution, avoid high doses.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No specific pharmacokinetic studies for the combination; however, pregnancy increases renal clearance of aspirin, requiring dose adjustments for anti-inflammatory effect. Caffeine clearance decreases in later pregnancy; orphenadrine metabolism may be altered but data insufficient. Use lowest effective dose for shortest duration.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Orphenadrine citrate has anticholinergic properties; use cautiously in patients with glaucoma, urinary retention, or myasthenia gravis. Aspirin component increases bleeding risk, especially with concurrent anticoagulants. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of salicylism with high doses or hepatic impairment.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take with food to reduce gastrointestinal upset.,Avoid alcohol while taking this medication.,Do not exceed recommended dosage; may cause dizziness or drowsiness.,Discontinue and seek medical attention if you experience signs of bleeding (e.g., black stools) or allergic reaction.,Inform your doctor if you have a history of stomach ulcers, bleeding disorders, or asthma.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
"Orphenadrine, a centrally acting muscle relaxant with sedative and anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of Ketazolam, a benzodiazepine anxiolytic. This synergistic pharmacodynamic interaction leads to enhanced sedation, impaired cognitive function, and increased risk of falls or respiratory depression, particularly in elderly or debilitated patients. The combination may also exacerbate anticholinergic side effects such as confusion and urinary retention."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, may enhance the central nervous system depressant effects of lithium cation, an antimanic agent. This additive pharmacodynamic interaction can lead to increased sedation, dizziness, and confusion, potentially impairing cognitive and motor function. Clinically, patients may experience exacerbated lithium-induced neurotoxicity, manifesting as tremor, ataxia, or altered mental status, particularly in elderly or renally impaired individuals."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of ethylmorphine, an opioid analgesic. This additive pharmacodynamic interaction may lead to enhanced sedation, respiratory depression, and psychomotor impairment, increasing the risk of falls, cognitive dysfunction, and potentially fatal respiratory compromise, particularly in elderly or debilitated patients."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs CARISOPRODOL COMPOUND, answered by our medical review team.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is a Skeletal Muscle Relaxant that works by Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is: 1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is classified as Category A/B. First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.